Skip to main content

Table 4 clinical characteristics of thyroid dysfunction related to PD-1 monoclonal antibody therapy in primary liver cancer

From: Immune checkpoint blockade PD-1 therapy for primary liver cancer: incidence and influencing factors of thyroid dysfunction

 

Primary thyroid dysfunction (n = 93)

Secondary thyroid dysfunction (n = 20)

P

t/ x2/Z

Gender (n, %)

  

0.264

1.247

 Male

68(73.1)

17(85.0)

  

 Female

25(26.9)

3(15.0)

  

Age(years,x ± s)

58.0 ± 10.7

61.6 ± 9.9

0.174

1.368

BMI

22.1 ± 2.7

23.6 ± 3.5

0.132

1.520

Diabetes

  

1.000

0.000

 Yes

15(16.1)

3(15.0)

  

 No

78(83.9)

17(85.0)

  

Evaluation time [weeks,M(Q1,Q3)]

12.0(3.0, 27.8)

10.0(3.3, 17.8)

0.412

0.821

Hepatocellular carcinoma (n,%)

  

0.936

0.007

 Yes

87(93.5)

18(90.0)

  

 No

6(6.5)

2(10.0)

  

Staging of BCLC system(n,%)

  

0.350

0.875

 B

19(20.4)

6(30.0)

  

 C

74(76.0)

14(70.0)

  

HBV or HCV(n,%)

83(77.4)

19(85.0)

0.710

0.138

Cirrhosis (n,%)

74(80.5)

18(87.8)

0.441

0.595

Decompensation stage (n,%)

27(36.5)

15(83.3)

0.002

9.166

 Yes

41(63.5)

3(16.7)

  

 No

    

Previous or combined treatment (n,%)

15(16.1)

1(5.0)

0.346

0.887

 Surgical resection

69(74.2)

16(80.0)

0.795

0.086

 TAE or TACE

43(46.2)

12(60.0)

0.264

1.248

 Tumor ablation

68(73.1)

9(45.0)

0.014

5.995

 Targeted agent

5(5.4)

1(5.0)

1.000

0.000

 Systemic chemotherapy

12(12.9)

2(10.0)

1.000

0.000

 Radiotherapy

12(12.9)

1(5.0)

0.536

0.383

Name of PD-1 monoclonal antibody (n,%)

  

0.319

0.992

 Sintilimab

50(53.8)

9(45.0)

  

 Camrelizumab

43(46.2)

11(55.0)

  

Thyroid antibody (n,%)

  

0.036

-

 Positive

7(31.8)

0(0.0)

  

 Negative

15(68.2)

12(100.0)

  
  1. BCLC:Barcelona Clinic Liver Cancer; TAE: transarterial embolization;TACE: transar-terial chemoembolization; PD-1: programmed cell death protein 1; TSH: abnormal thyroid stimulating hormone; FT4: free thyroxine 4; FT3: free thyroxine 3